
Halifax, Nova Scotia, 30 September, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific

The management and board is delighted to have Dr. Ratnam joining our growing team and support MedMira’s various regulatory applications. Dr. Ratnam brings over 40

MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The Company has been successful in its

Halifax, Nova Scotia, 26 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) received the confirmation letter from the John Hopkins School of Medicine, Division

MedMira is continuously developing more ways to expand on future potentials of its RVF Technology, if this is customer satisfaction, increase of output or supporting

Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new

Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its

Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving
Contacts Investor Relations
For more information about MedMira or inquiries related to Investor Relations, please contact us. Our Investor relations team will get back to you immediately.
Corporate Headquarters
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada
Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com